|
| NOVEMBER
12, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
CONTINUING NEXT WEEK! |
| We
will have our next CEO Q&A next week
with Oren Gilad, President and CEO, Aprea
Therapeutics - check out our previous
Q&As here. More |
|
|
|
Our
Newest Location: Mispro San
Diego!
Reserve your space today in
our Sorrento Mesa
Contract Vivarium |
|
Learn More
→ |
|
|
- Lumos:
Expands FebriDx Across 97 Additional
WellStreet Urgent Care Locations More
- Oncolytics
Biotech: Clinical Supply Agreement to
Evaluate Pelareorep in Combination With
LOQTORZI (toripalimab-tpzi) in Squamous Cell
Anal Carcinoma More
- Tandem
Diabetes Care: Receives Multiple Health Canada
Approvals for t:slim X2 Insulin Pump More
|
|
 |
|
|
Investment Banking Advisory to the
Life Science Industry |
|
Learn More
→ |
|
|
- Artelo Biosciences: Provides Business Update
and Reports 2026 Third Quarter Financial
Results More
- Axiom Biosciences: Regulation Crowdfunding
Offering With Wefunder Community Round More
- Belite Bio: Unaudited Third Quarter 2026
Financial Results and Provides a Corporate
Update More
- Bionano: Third Quarter 2026 Results and
Provides a Business Update More
- Carlsmed: Third Quarter 2026 Financial
Results and Raises Full-Year Guidance More
- Capricor Therapeutics: Third Quarter 2026
Financial Results and Provides Corporate
Update More
- Cardiff Oncology: Third Quarter 2026 Results
and Provides Business Update More
- Dermata Therapeutics: Provides Corporate
Update and Reports Financial Results for the
Third Quarter 2026 More
- Gossamer Bio: Third Quarter 2026 Financial
Results and Provides Business Update More
- Kura Oncology: Third Quarter 2026 Financial
Results and Corporate Update More
- Palisade Bio: Third Quarter 2026 Financial
Results and Advances PALI-2108 Phase 2
Clinical Development Programs More
- Where Tech Meets Bio: Weekly Tech+Bio #90 -
AI Momentum Moves Into Clinical Trials —
Companies to Watch in 2026 More
|
|
- Biotech & Pharma Updates | November 10,
2026 More
- LJI: New 'FITdb' Database Reveals the
Genetic Drivers of Immune Cell Function More
- SciLnq: Therapeutic Antibody
Development Consulting More
- Subscribe to LifeSci Startup for
Updates on US Startups More
- Tandem Recalls Mobi Insulin Pump, Reports
230 Adverse Events More
|
|
 |
 |
| Slone
Partners Places Farhad Ghavami as
Chief Executive Officer at
SeqCenter |
|
Learn More
→ |
|
|
- Biopharma Layoffs Rise YOY in October But
Sharply Trend Down for 2026 More
- 2026 Q3 Job Market Report: Job
Opportunities, Layoffs Show YOY Improvement More
- ICYMI: BioSpace 2027 Best Places to Work
Shines Light on Most Admired Employers More
- ICYMI: More on Tandem Diabetes Care Naming
Next CEO More
- ICYMI: Slone Partners Places David Stern as
Chief Executive Officer of Mirvie More
- ICYMI: Vertex Lays Off 78 Crinetics Staffers
Amid $10B Integration More
- OPPORTUNITY: Director of Compliance, Remote
More
- OPPORTUNITY: Head of Market Development
& Strategy, California More
- OPPORTUNITY: Senior Vice President,
Regulatory Affairs & Quality Assurance,
Boston More
- Slone Partners: Behind the
Search - A Conversation with Slone Partners
Senior Partner Kim Wilson More
- Slone Partners: Doing More With Less
- Building the Right Nonprofit Leadership
Team in a Resource-Constrained Environment More
- Slone Partners: Leading Through AI - The New
Playbook for HealthTech Executives More
- VETmAb Biosciences: Appoints Katja Buhrer
as Chief Operating Officer More
|
|
 |
|
DISCOVER COMPANIES |
|
Big4Bio: San Diego Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
|
|
|
|
|
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:San
Diego, all rights reserved
2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|